Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theriva Biologics ( (TOVX) ) has provided an announcement.
On August 29, 2025, Theriva Biologics, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were approved. The company operates in the biotechnology industry, focusing on developing innovative therapeutics. During the meeting, stockholders approved an amendment to the 2020 Stock Incentive Plan, increasing the number of shares authorized for issuance from 2,500,000 to 4,500,000. Additionally, the election of directors, ratification of the auditor, and advisory votes on executive compensation were conducted, with the decision to hold future advisory votes on executive compensation every three years.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Average Trading Volume: 548,324
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.91M
See more data about TOVX stock on TipRanks’ Stock Analysis page.